Navigation Links
Penn study demonstrates new way to boost immune memory

PHILADELPHIA - After a vaccination or an infection, the human immune system remembers to keep protecting against invaders it has already encountered, with the aid of specialized B-cells and T-cells. Immunological memory has long been the subject of intense study, but the underlying cellular mechanisms regulating the generation and persistence of long-lived memory T cells remain largely undefined. Now, University of Pennsylvania School of Medicine researchers have found that a common anti-diabetic drug might enhance the effectiveness of vaccines. The findings are described this week in an advanced online publication of Nature.

In this study, an experimental preventive vaccine was made more efficacious by boosting numbers of cancer fighting T cells with the anti-diabetic drug metformin. This resulted in a larger population of memory immune cells that were able to fight off a tumor at a later time.

"We serendipitously discovered that the metabolizing, or burning, of fatty acids by T cells following the peak of infection is critical to establishing memory in those T cells," says senior author Yongwon Choi, PhD, Professor of Pathology and Laboratory Medicine. "As a consequence, we used the widely prescribed anti-diabetic drug metformin, which is known to operate on fatty-acid metabolism, to enhance this process."

"We have shown experimentally in mice that metformin increases T-cell memory as well as the ensuing protective immunity of an experimental anti-cancer vaccine," notes postdoctoral fellow and first author Erika Pearce, PhD.

"These findings were unanticipated, but are potentially extremely important and could revolutionize current strategies for both therapeutic and prophylactic vaccines," says Choi.

The lab developed mice deficient in TRAF6, a protein important in the immune response. They found that CD8 T cells deficient in TRAF6 mount an initial response, meaning they are able to proliferate into an army of so-called effector cells that can clear infection. However, TRAF6-deficient CD8 T cells do not develop into a population of memory cells that can recall a particular infectious agent when the body encounters it a second time.

Using microarray analysis and a program that searches protein pathways, the team compared the gene expression profiles of TRAF6-deficient cells and cells with TRAF6 to see what stood out. "We discovered differences in genes that regulate fatty acid metabolism," says Pearce. Fatty acids can be broken down for energy and the microarray analyses revealed that TRAF6-deficient CD8 T cells exhibit altered expression of genes that regulate this process.

Consistent with the microarray findings, CD8 T cells lacking TRAF6 display defective fatty acid oxidation in response to growth factor withdrawal. Giving the mutant mice the metformin restored fatty acid oxidation and the generation of memory cells that lack TRAF6. Remarkably, this treatment also increased the generation of memory cells in normal mice, and consequently was able to significantly improve the efficacy of an experimental anti-cancer vaccine. A lack of fatty acid metabolism is correlated with lack of T-cell memory and through in vitro studies the team also saw that T cells burn more fatty acids when given metformin.

T cells proliferating to form an army of effector cells burn glucose for their energy. Non-proliferating T cells, such as memory cells, burn fatty acids, amino acids, and glucose interchangeably in a different metabolic pathway. From this, explains Pearce, "it is implied that there's a switch in metabolism somewhere along the way between proliferating and non-proliferating T cell populations." Perhaps at the peak of the proliferation, when energy is limiting and cells are metabolically stressed, there is a switch to another energy pathway to survive, say from glucose to fatty acids.

"Most T cell vaccines have a good initial response, but the development of long-term T memory cells has been difficult to achieve," says Choi. "The key improvement we're hoping to contribute is to use the traditional vaccine, then with the proper timing, we can use metformin, in theory, to boost the development of memory cells. We want to enhance immunity after an initial vaccination so we can make vaccines that are being tested now better."


Contact: Karen Kreeger
University of Pennsylvania School of Medicine

Related medicine news :

1. Health Plans Prepare for Health Care Reform: Comparative Effectiveness, Consumerism Drive Future Changes, According to Deloitte Study
2. Study gives clues to how adrenal cancer forms
3. Protein may be strongest indicator of rare lung disease, study shows
4. People who wear rose-colored glasses see more, University of Toronto study shows
5. 5 Spanish centers join a study for a new leukemia and lymphoma treatment technique
6. Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimers
7. FDA to Study Ways to Be More Open With Public
8. Study further expands understanding of leptins role in brain neurocircuitry
9. NASA Selects Four Proposals to Study Space Radiation Risks
10. Study Results Show CAQH CORE Certification Dramatically Cuts Administrative Costs, Accelerates I.T. Adoption by Providers and Health Plans
11. Study: Benefit to women not enough to sway men to get HPV vaccine
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... variables that determine which patients are or are not eligible for bariatric surgery. The ... BMI over 40, are more than 100 pounds overweight, or have a BMI of ...
(Date:11/24/2015)... ... 24, 2015 , ... It takes only three to five seconds to make ... the first impression be positive and reflects business values. If a client starts with ... want to return. They will also share their thoughts about a business with others, ...
(Date:11/24/2015)... ... 24, 2015 , ... Cancer patients, survivors, caregivers, family members ... live taping of the next CURE Connections® video series on Saturday, ... Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the ... study designed to yield insights into how to detect and treat pancreatic cancer (PC). ... cancer from small, non-coding RNA molecules (ncRNA), genetic material that is present in the ...
(Date:11/24/2015)... ... 2015 , ... Sir Grout of Baltimore is proud to ... award recognizes good companies for excellence in service and a commitment to the ... surface restoration company earned this recognition after a thorough review by the acclaimed ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Connecticut , November 24, 2015 ... of Acadiana has entered into a multi-year agreement ... imaging centers. This investment will provide the Breast Center ... --> Sectra (STO: SECT B) announces that ... agreement to deploy Breast Imaging PACS in its ...
(Date:11/24/2015)... , Nov. 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ... its Board of Directors has declared a special 1 percent ... dividend is payable December 14, 2015, to shareholders of record ... form of additional shares of common stock. ... Board is a strong endorsement of our confidence in Ascendant,s ...
(Date:11/24/2015)... -- iRhythm Technologies, Inc. , a leading digital health care ... will participate in the 27th Annual Piper Jaffray Healthcare Conference at ... . Kevin King , Chief Executive Officer of ... 8:50am ET. --> --> ... . --> iRhythm is a privately held ...
Breaking Medicine Technology: